Filing Details
- Accession Number:
- 0001209191-18-040965
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-07-03 16:10:54
- Reporting Period:
- 2018-07-02
- Accepted Time:
- 2018-07-03 16:10:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578696 | David Davidson | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-07-02 | 10,000 | $5.50 | 34,905 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-07-02 | 2,818 | $153.36 | 32,087 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-07-02 | 5,982 | $154.07 | 26,105 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-07-02 | 1,200 | $154.85 | 24,905 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-07-02 | 10,000 | $0.00 | 10,000 | $5.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 53,951 | 2023-01-16 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
- The range in prices for the transaction reported on this line was $152.70 to $153.6750. The average weighted price was $153.3564. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $153.70 to $154.65. The average weighted price was $154.0672. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $154.75 to $155.00. The average weighted price was $154.8463. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of April 1, 2013 and May 1, 2013. The shares underlying these options vested as follows: 25% vested on April 1, 2014 and May 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years.
Billionaire Hedge Funds
